By Rex Clements, Head of Global Franchises at Sandoz.
A tenth anniversary could be a fairly unremarkable date in healthcare, but 2016 marked the coming of age of biosimilars – and the next decade is full of promise for patients.
Fly over Australia’s outback, visit a midwife in Ethiopia and learn about how we can make life-changing biologic medicines accessible for more patients - in the new issue of ‘Making Access Happen - For better healthcare around the world’
Lord Jim O’Neill, the author of the UK government-commissioned Review on AMR, has called on the pharmaceutical industry to “think more broadly” about the role it can play in combatting the growing global threat of antimicrobial resistance (AMR).
Since the early 2000s, according to the World Health Organization, some 6.3 million malaria deaths have been prevented. This is the result of broad educational programs, the use of insect-repellant nets and active improvements in access to artemisinin-based treatment. Still, more than 400,000 people die each year of malaria. To save even more lives, UN Senior Advisor Alan Court recommends reducing inefficiencies through public-private partnerships.
Sheila Frame, VP and Head of Biopharmaceuticals in North America, reflects on the newly published RAND report highlighting the potential USD 54 billion in cost savings offered by the expansion of biosimilars in the US.
This site is intended for a global audience